This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claim 1-39 (canceled)

Claim 40: (currently amended) A non-tumorigenic cellular immunogen which promotes tumor regression in a host, said non-tumorigenic cellular immunogen comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming cognate transgene ~~derived by deletion of~~ having a deletion mutation in a sequence of the transgene ~~essential~~ required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the ~~deleted sequence~~ deletion mutation, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of and the target proto-oncogene is selected from the group consisting of AKT-*2*, *c-erbB-2* (HER2/*neu*), MDM-*2*, *c-myc*, *c-myb*, *c-ras*, *c-src* and *c-yes*.

Claim 41: (currently amended) A method for preparing a non-tumorigenic cellular immunogen which promotes tumor regression in a host, the method comprising:

transfecting cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to the target proto-oncogene, said non-transforming cognate transgene ~~derived by deletion of~~ having a deletion mutation in a sequence of the transgene ~~essential~~ required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the ~~deleted sequence~~ deletion mutation, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of AKT-*2*, *c-erbB-2* (HER2/*neu*), MDM-*2*, *c-myc*, *c-myb*, *c-ras*, *c-src and c-yes*.

Claim 42: (currently amended) A non-tumorigenic cellular immunogen which promotes tumor regression in a host, said non-tumorigenic cellular immunogen comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming

cognate transgene ~~derived by deletion of~~ having a deletion mutation in a sequence of the transgene ~~essential~~ required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the ~~deleted sequence~~ deletion mutation, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of *c-erbB-2* (HER2/*neu*), *c-myc* and *c-src*.

Claim 43: (currently amended) A method for preparing a non-tumorigenic cellular immunogen which promotes tumor regression in a host, the method comprising:

transfecting cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming cognate transgene ~~derived by deletion of~~ having an deletion mutation in a sequence of the transgene ~~essential~~ required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the ~~deleted sequence~~ deletion mutation, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein the

target proto-oncogene is selected from the group consisting of *c-erbB-2* (HER2/*neu*), *c-myc* and *c-src*.